Minerva Neurosciences Inc

NERV

Company Profile

  • Business description

    Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

  • Contact

    1500 District Avenue
    BurlingtonMA01803
    USA

    T: +1 617 600-7373

    E: [email protected]

    https://www.minervaneurosciences.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    8

Stocks News & Analysis

stocks

Our top ASX picks in every sector

These companies are our top choices for investors wanting to boost Aussie exposure.
stocks

Potentially catastrophic ruling for ASX company

We raise our risk and uncertainty rating to reflect the impact of the ruling.
stocks

4 charts on Nvidia’s record $4 trillion market cap

Shares of the semiconductor giant have rocketed 280% over the past two years amid the AI boom.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,854.5039.200.44%
CAC 407,808.1721.12-0.27%
DAX 4024,160.6494.67-0.39%
Dow JONES (US)44,459.6588.140.20%
FTSE 1008,998.0656.940.64%
HKSE24,479.98276.661.14%
NASDAQ20,640.3354.800.27%
Nikkei 22539,570.24110.620.28%
NZX 50 Index12,679.360.670.01%
S&P 5006,268.568.810.14%
S&P/ASX 2008,610.7040.300.47%
SSE Composite Index3,523.273.620.10%

Market Movers